• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Androgen deprivation therapy toxicity and management for men receiving radiation therapy.接受放射治疗的男性的雄激素剥夺疗法毒性及管理
Prostate Cancer. 2012;2012:580306. doi: 10.1155/2012/580306. Epub 2012 Dec 30.
2
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.局部晚期前列腺癌的短期雄激素剥夺与放疗：跨塔斯曼放射肿瘤学组96.01随机对照试验的结果
Lancet Oncol. 2005 Nov;6(11):841-50. doi: 10.1016/S1470-2045(05)70348-X.
3
[Radiation therapy of locally advanced prostate cancer].[局部晚期前列腺癌的放射治疗]
Urologe A. 2017 Nov;56(11):1402-1409. doi: 10.1007/s00120-017-0511-4.
4
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.雄激素剥夺治疗时机对 PSA 升高的前列腺癌患者的影响（TROG 03.06 和 VCOG PR 01-03 [TOAD]）：一项随机、多中心、非盲、3 期临床试验。
Lancet Oncol. 2016 Jun;17(6):727-737. doi: 10.1016/S1470-2045(16)00107-8. Epub 2016 May 4.
5
MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.MDM2抑制以p53依赖的方式使前列腺癌细胞对雄激素剥夺和放疗敏感。
Neoplasia. 2016 Apr;18(4):213-22. doi: 10.1016/j.neo.2016.01.006.
6
Evolution of definitive external beam radiation therapy in the treatment of prostate cancer.前列腺癌根治性外照射放疗的演变。
World J Urol. 2020 Mar;38(3):565-591. doi: 10.1007/s00345-019-02661-6. Epub 2019 Mar 8.
7
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.局部晚期前列腺癌男性患者的短期雄激素抑制和放疗与中期雄激素抑制和放疗，联合或不联合唑来膦酸治疗（TROG 03.04 RADAR）：一项随机、3 期、析因试验的 10 年结果。
Lancet Oncol. 2019 Feb;20(2):267-281. doi: 10.1016/S1470-2045(18)30757-5. Epub 2018 Dec 19.
8
Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.死亡率与雄激素剥夺疗法作为临床局限性前列腺癌初始治疗后生化复发的挽救性治疗手段
J Urol. 2017 Jun;197(6):1448-1454. doi: 10.1016/j.juro.2016.12.086. Epub 2016 Dec 19.
9
Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.接受原发性雄激素剥夺治疗的临床局限性前列腺癌患者患糖尿病的风险。
J Urol. 2015 Jun;193(6):1956-62. doi: 10.1016/j.juro.2014.12.027. Epub 2014 Dec 15.
10
Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation?运动能否改善前列腺癌患者雄激素剥夺治疗初期的治疗毒性？与延迟康复相比，这是否更有效？
BMC Cancer. 2012 Sep 26;12:432. doi: 10.1186/1471-2407-12-432.

引用本文的文献

1
Selection criteria for initiation and renewal of luteinizing hormone-releasing hormone agonist therapy in patients with prostate cancer: a French prospective observational study.前列腺癌患者促黄体生成素释放激素激动剂治疗启动和维持的选择标准：一项法国前瞻性观察研究。
Ther Adv Urol. 2014 Dec;6(6):205-14. doi: 10.1177/1756287214542418.
2
Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer.英国关于前列腺癌根治性放疗和雄激素剥夺治疗所致勃起功能障碍管理指南的制定。
Int J Clin Pract. 2015 Jan;69(1):106-23. doi: 10.1111/ijcp.12512. Epub 2014 Oct 6.

本文引用的文献

1
Standards of medical care in diabetes--2012.《糖尿病医疗护理标准——2012》
Diabetes Care. 2012 Jan;35 Suppl 1(Suppl 1):S11-63. doi: 10.2337/dc12-s011.
2
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.雄激素剥夺疗法与前列腺癌患者心血管死亡的相关性：随机试验的荟萃分析。
JAMA. 2011 Dec 7;306(21):2359-66. doi: 10.1001/jama.2011.1745.
3
Radiotherapy and short-term androgen deprivation for localized prostate cancer.放疗联合短期雄激素剥夺治疗局限性前列腺癌。
N Engl J Med. 2011 Jul 14;365(2):107-18. doi: 10.1056/NEJMoa1012348.
4
Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?雄激素剥夺疗法治疗前列腺癌：日益增长的担忧是否导致其应用减少？
BJU Int. 2011 Nov;108(10):1588-96. doi: 10.1111/j.1464-410X.2011.10127.x. Epub 2011 Mar 31.
5
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.局部晚期前列腺癌的短期新辅助雄激素剥夺和放疗：来自 TROG 96.01 随机试验的 10 年数据。
Lancet Oncol. 2011 May;12(5):451-9. doi: 10.1016/S1470-2045(11)70063-8.
6
Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.接受雄激素剥夺治疗的非转移性前列腺癌患者的骨骼和代谢健康。
Med J Aust. 2011 Mar 21;194(6):301-6. doi: 10.5694/j.1326-5377.2011.tb02979.x.
7
Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?雄激素剥夺疗法在前列腺癌男性患者中的应用：如何监测和治疗其副作用？
Clin Endocrinol (Oxf). 2011 Mar;74(3):289-93. doi: 10.1111/j.1365-2265.2010.03939.x.
8
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.高危转移性前列腺癌的外照射放疗或联合长期雄激素抑制治疗：EORTC 随机研究的 10 年结果。
Lancet Oncol. 2010 Nov;11(11):1066-73. doi: 10.1016/S1470-2045(10)70223-0. Epub 2010 Oct 7.
9
Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy.雄激素剥夺治疗的前列腺癌男性患者的骨微观结构的结构性衰减。
J Clin Endocrinol Metab. 2010 Dec;95(12):E456-63. doi: 10.1210/jc.2010-0902. Epub 2010 Sep 29.
10
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.托瑞米芬降低接受雄激素剥夺治疗的前列腺癌男性骨折风险。
J Urol. 2010 Oct;184(4):1316-21. doi: 10.1016/j.juro.2010.06.022. Epub 2010 Aug 17.

接受放射治疗的男性的雄激素剥夺疗法毒性及管理

Androgen deprivation therapy toxicity and management for men receiving radiation therapy.

作者信息

Johnson Matthew E, Buyyounouski Mark K

机构信息

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

出版信息

Prostate Cancer. 2012;2012:580306. doi: 10.1155/2012/580306. Epub 2012 Dec 30.

DOI:10.1155/2012/580306
PMID:23326671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3544287/
Abstract

Androgen deprivation therapy is commonly used in combination with radiotherapy as part of the definitive treatment for men with clinically localized and locally advanced prostate cancer. Androgen deprivation has been associated with a wide range of iatrogenic effects impacting a variety of body systems including metabolic, musculoskeletal, cardiovascular, neurocognitive, and sexual. This review aims to provide the radiation oncology community with the knowledge to monitor and manage androgen deprivation therapy toxicity in an effort to provide the highest level of care for patients and to minimize the iatrogenic effects of androgen deprivation as much as possible.

摘要

雄激素剥夺疗法通常与放射疗法联合使用，作为临床局限性和局部晚期前列腺癌男性患者确定性治疗的一部分。雄激素剥夺与一系列医源性效应相关，这些效应会影响包括代谢、肌肉骨骼、心血管、神经认知和性功能在内的多种身体系统。本综述旨在为放射肿瘤学界提供相关知识，以监测和管理雄激素剥夺疗法的毒性，从而为患者提供最高水平的护理，并尽可能减少雄激素剥夺的医源性效应。